Background: COPD pathology involves not only the lungs but also extrapulmonary abnormalities. Osteoporosis is one of the most important abnormalities because it may cause vertebral compression fractures and deteriorate pulmonary function. COPD patients have many risk factors for osteoporosis, such as low BMI, decreased activity, systemic infl ammation, and use of corticosteroids. Some of these factors have been shown to deteriorate with COPD exacerbations. We previously demonstrated the correlation between emphysema and osteoporosis and between emphysema progression and COPD exacerbations. Thus, the hypothesis that exacerbation causes osteoporosis progression in COPD patients was investigated. Methods: Forty-two COPD patients not on osteoporosis treatment for over 2 years were recruited. During follow-up, exacerbations had been prospectively recorded. Thoracic vertebral bone mineral density (BMD) was measured using chest CT, and the annual change in BMD was calculated. The change was compared between patients with and without a history of exacerbations. Results: The decrease in thoracic vertebral BMD was greater in patients with than in those without a history of exacerbations (median ΔBMD mg/ml⋅year: -3.78 versus -0.30, p = 0.02). Moreover, multivariate regression analysis showed that exacerbations and baseline PaO 2 were independent predictors of the BMD decrease (R
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because it may cause vertebral compression fractures (VCF) that can deteriorate pulmonary function. It has been reported that the prevalence of VCF in COPD patients is high (24% to 63%) ( 2 ) , and one compression fracture in the thoracic vertebra results in a 9% decrease in vital capacity and impairment in FEV 1 in COPD patients ( 3, 4 ) .
Th e common features in COPD patients, such as low body mass index (BMI), history of smoking, age, inactivity, systemic infl ammation, and the use of systemic corticosteroids, are important risk factors for osteoporosis ( 3 ) . Moreover, we previously reported that severity of emphysema was closely related to loss of vertebral bone mineral density (BMD) assessed by chest computed tomography (CT) scan ( 5 ) , and our fi ndings were subsequently confi rmed by other investigators using conventional osteoporosis indices (Dual-emission X-ray absorptiometry) ( 6 ) . Th ese fi ndings suggest that COPD pathology is closely linked to osteoporosis.
Exacerbation is an important issue in COPD because it has negative impacts on FEV 1 ( 7, 8 ) , health status ( 9 ), survival ( 10, 11 ) , the BODE index ( 12 ) , and socioeconomic costs ( 13 ) . Exacerbations also cause deterioration in several risk factors for osteoporosis, such as inactivity ( 12 ) and systemic infl ammation ( 14 ) , and the use of systemic corticosteroids during exacerbations may accelerate BMD loss ( 11 ) . Moreover, we recently reported that exacerbations accelerated emphysematous change ( 15 ) . Th us, we speculated that exacerbations may accelerate not only parenchymal destruction but also BMD loss. However, to the best of our knowledge, no longitudinal study has examined the relationship between COPD exacerbations and osteoporosis progression.
Using chest CT scan images, BMD of the thoracic vertebrae and emphysematous changes can be evaluated simultaneously ( 16, 17 ) . Moreover, BMD of the vertebra assessed by chest CT scan is better than that assessed by dual X-ray absorption to predict vertebral VCFs ( 18 ) . In the present study, the longitudinal impact of exacerbations on thoracic vertebral BMD was explored using chest CT scan data.
Methods
Subjects
Th is is a part of prospective observational study investigating COPD exacerbation ( 12 , 15 , 19 ) . Th e patient inclusion criteria were: ( 1 ) COPD diagnosed according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease ( 1 ); and ( 2 ) the patient agreed to prospectively record exacerbations. Th e exclusion criteria were: ( 1 ) history of respiratory diseases other than COPD; ( 2 ) occurrence of malignancy within the previous 5 years; ( 3 ) history of bone disease; ( 4 ) receiving osteoporosis treatment such as bisphosphonates and alfacalcidol (vitamin D analogue); ( 5 ) currently receiving oral systemic corticosteroid therapy; ( 6 ) receiving rehabilitation during the study; and ( 7 ) receiving home-oxygen therapy.
Th e study protocol is summarized in Figure 1 , and the details of patient disposition are provided in the result section. Briefl y, from March 2006 to May 2008, we enrolled 82 of 104 patients with COPD who agreed to record exacerbations prospectively. Th e observation period was 2 years. Finally, follow-up CT scans were performed 2 years after study entry in 42 patients. Th e subject population in the present study was almost the same as in our previous study ( 15 ) . Th e most notable difference between the two study populations was related to whether the patients receiving osteoporosis therapy were excluded. Th e ethics committee of Kyoto University approved the study (approval No. E182), and all patients provided their written informed consent to participate
Exacerbation criteria and defi nition of stable condition
Exacerbations were defi ned as symptomatic deterioration requiring medical treatment (antibiotics and/or systemic corticosteroids) ( 15 , 19 , 20 ) . Stable condition was defi ned as an exacerbation-free interval that lasted for more than 4 weeks. Symptomatic changes were assessed by a modifi ed version of the East London cohort study criteria ( 7 ) .
Pulmonary function tests, CT acquisition, and calibration of CT numbers
Baseline and 2-year follow-up CT scans (Aquilion 64; Toshiba, Tokyo, Japan; slice thickness, 0.5 mm) and pulmonary function tests (Chestac-65V; Chest MI Corp, Tokyo, Japan) were performed under stable conditions. All pulmonary function tests and CT scans were performed after inhaling short-acting bronchodilators (salbutamol and ipratropium) as previously reported ( 5 , 21 ) . CT numbers in the lung fi eld were corrected using tracheal air density to prevent the X-ray tube aging eff ect ( 15 , 22 ) .
Analysis of low attenuation areas
To evaluate pulmonary emphysema quantitatively, the low attenuation area percentage (LAA%) was measured according to our previous reports ( 5 , 23 ) .
Measurement of BMD in vertebral bone
Using a modifi ed method reported previously ( 5 , 17 ) , BMD was measured in the thoracic vertebral bones (T4, T7, T10) derived from the CT scan density. In a previous report, BMD was calculated using one chest CT scan slice, but in the present study, it was calculated using fi ve chest CT scan slices. Briefl y, fi rst a mid-vertebral slice was selected using reconstructed images (sagittal and coronal images) from 0.5-mm slice thickness CT images. Th en, the elliptical region of interest (ROI) was encompassed manually as the largest possible area at the anterior portion of each vertebral body on fi ve slices whose center was the chosen mid-vertebral slice. Finally, the mean CT scan density of the ROI was measured. As in our previous report ( 5 ), BMD was calculated based on mean CT scan density using the formula (BMD (in milligrams per milliliter) = 0.767 × CT scan density (in HU) + 3.37). Th is calculating formula was validated in our previous report using calibration phantom which contained eight tubes of known concentration of hydroxyapatite ( 5 ) . All images were measured by two pulmonologists (H.K. and N.T.) to minimize interobserver variability of the measurements, and their measurements were then averaged to obtain fi nal values.
Measurement of the change in BMD
Th e annual change in BMD (ΔBMD) was defi ned as follows: ΔBMD (in milligrams per milliliter per year ) = ((BMD after two-year follow-up)-(BMD at baseline)) / (follow-up span (in years)).
Annual BMD percentage change normalized with baseline BMD was adjusted as follows:
ΔBMD/base (in percentage per year) = (ΔBMD/(BMD at baseline)) × 100
Statistical analyses
All statistical analyses were performed using JMP 7 software (SAS Institute; Cary, NC). Th e data are expressed as medians (25 th , 75 th percentile) unless otherwise indicated. Th e diff erences between groups were evaluated using the Mann-Whitney U-test. Data within groups were analyzed with the Wilcoxon signed-rank test. Relationships among data were assessed by Spearman's rank correlation test. To evaluate the relative contribution of exacerbations to the decrease in thoracic vertebral BMD, multivariate regression analysis was performed. A p-value less than 0.05 was considered signifi cant.
Results
Patient characteristics
Baseline CT scans were performed on 82 patients who had participated in our prospective observational study investigating COPD ( 15 , 19 , 20 ) . Of these patients, 14 were excluded because of abnormal chest shadows not associated with emphysematous changes seen on chest CT images at entry ( Figure 1 ). Over the two-year followup, 26 patients were excluded for the following reasons: withdrawal of consent, appearance of a new shadow, serious condition, death, vertebral bone fracture, or lost to follow-up. Table 1 shows the characteristics of the study subjects (42 patients) who completed all of the follow-up examinations, including baseline and 2-year follow-up chest CT scans. During the observational period, 13 patients experienced exacerbations requiring treatment with antibiotics and/or systemic corticosteroids at least once, and 29 patients experienced no exacerbations. Of 13 patients with a history of exacerbations, only 1 patient received systemic corticosteroid treatment (methylprednisolone 16 mg/day for 5 days). Th ere were no signifi cant diff erences in baseline clinical parameters, pulmonary function, CT parameters, or BMD between the groups (Table 2 ). Baseline pharmacological treatment including inhaled corticosteroids was not signifi cantly diff erent between the groups.
Impact of exacerbations on BMD, lung functions, and emphysematous change
Changes in BMD, lung functions, emphysematous change, and PaO 2 between patients with and without a history of exacerbations are shown in Table 3 . In patients who experienced exacerbations, BMD and BMD/base decreased signifi cantly after the follow-up period, whereas these parameters did not change in patients who experienced no exacerbations. Th e median annual changes in BMD and BMD/base were signifi cantly greater in patients with than in those without exacerbations (ΔBMD mg/ml·year: −3.78 versus −0.30, p = 0.01, ΔBMD/base %: −5.41 versus −0.60, p = 0.02) (Table 2 , Figure 2 ).
In agreement with our previous report (15) , LAA% also increased signifi cantly after the observation period in patients who experienced exacerbations (p = 0.01) ( Table 3 ) , whereas this parameter did not change in patients who experienced no exacerbations. Th ere were no signifi cant annual changes in pulmonary function test results such as FEV 1 and D LCO between the groups. Table 4 shows the correlation between the annual change in BMD and associated factors for osteoporosis (exacerbation frequency and factors that have been shown to be associated with osteoporosis). Th e annual change in BMD was signifi cantly correlated with the exacerbation frequency (Spearman's rank correlation coeffi cient ρ = -0.37, p = 0.02). On univariate analysis, baseline FEV 1 was associated with the change in BMD (p = 0.04) whereas other factors such as BMI, smoking history, %FEV 1 predict, and LAA% were not.
On stepwise multivariate regression analysis (Table 5 ) to examine the relative contribution of each variable to 
Discussion
In the present study, the analysis showed that a decrease in thoracic vertebral BMD was signifi cantly associated with COPD exacerbations and baseline PaO 2 , while other factors known as risk factors for osteoporosis were not associated with the annual change in thoracic vertebral BMD. To the best of our knowledge, this is the fi rst longitudinal study that investigated the impact of exacerbations on comorbidity in COPD patients.
In COPD patients, various risk factors, such as low BMI, smoking, age, inactivity, systemic infl ammation, use of systemic corticosteroids ( 3 ), and LAA%, can be associated with osteoporosis ( 5 ) . Although most of them are still controversial, only LAA% ( 5,6 ) and BMI ( 5 , 24 ) has been confi rmed to correlate with BMD in cross-sectional studies. Osteoporosis is known as one of the common systemic manifestations in COPD ( 3 ), but the pathogenesis of osteoporosis in COPD patients has not been fully understood. Considering our result that the exacerbation frequency was signifi cantly correlated with the decrease in thoracic vertebral BMD, the factors involved in exacerbations could be precipitating key factors and cause the adverse eff ect.
Of these factors, systemic infl ammation is thought to play an important role in the progression of osteoporosis in COPD patients ( 3 , 25 ) . In fact, tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) have been reported to be associated with osteoporosis in COPD patients ( 26 ) , and both factors are known to stimulate osteoclasts and increase bone resorption through RANKL-mediated bone resorption in vitro ( 27 ) . In patients with exacerbations, the levels of various proinfl ammatory markers, such as IL-6, were reported to be elevated ( 14 ) . Th e elevated systemic infl ammatory markers, especially TNF-α and IL-6, in patients with exacerbations might have caused the deterioration in BMD in the present study. Further study is necessary to explore these ideas. It has been suggested that use of systemic steroids during exacerbations is one of the precipitating factors, but in the present study, only 1 of 13 patients with a history of exacerbations received systemic corticosteroid treatment. Even excluding this case, the study yielded the same conclusion. Th us, in clinical practice, it is important to pay attention to the patients who have a history of frequent exacerbations and treat them because they have a greater risk for osteoporosis progression, even if they do not receive systemic corticosteroids during exacerbations.
Multivariate analysis revealed that baseline PaO 2 was associated with the BMD decline independently of a history of exacerbations. Although no studies have shown that hypoxemia is associated with osteoporosis, baseline hypoxemia may refl ect the patients' dyspnea that causes inactivity, a risk factor for osteoporosis. Alternately, hypoxemia itself has adverse eff ects on osteoporosis in COPD patients ( 28 ) . To confi rm this fi nding and causal association, information about dyspnea and activity should be assessed in a future study.
We performed a preliminary study of the eff ect of osteoporosis therapy on the change in thoracic vertebral BMD. To explore the eff ect of osteoporosis therapy on BMD, we measured the change in BMD in 18 patients with a history of exacerbations using the same method as in the present study (online supplement e- Table 1 ). Osteoporosis therapy signifi cantly improved the decrease in BMD compared to no osteoporosis therapy in patients with a history of exacerbations (p = 0.002, online supplement e- Table 2 ). Th ese results suggest the potential of osteoporosis therapy, especially in patients with a history of exacerbations. Th is fi nding should be investigated in a future study.
Th is study had several limitations. First, the sample size was small. However, this was a single center study using only one scanner, so that the instability of CT scanners was less problematic than in multicenter studies.
In addition, exacerbations were prospectively recorded by at least two respiratory physicians who were unaware of CT data. Th ese advantages were thought suffi cient to overcome the small sample size. Moreover, one large observational study, the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points study (ECLIPSE study), showed that the co-existence of osteoporosis was associated with the occurrence of exacerbations in a cross-sectional cohort ( 29 ) . However, they did not examine the infl uence of exacerbations on osteoporosis progression. Th e fi ndings in the present longitudinal study further deepen our understanding of the relationship between COPD exacerbations and osteoporosis progression that ECLIPSE suggested. In the present study we could detect the progression of LAA in those who have a history of exacerbations, but couldn't detect the decline in FEV 1 . It is partly because this study was small sample study.
Second, BMD in the present study was calculated on the chest CT data using our formula that was validated in our previous report ( 5 ) . Th e data of the present study did not include Dual Energy X-ray Absorptiometry (DEXA), which is the standard method to estimate BMD. Th e lack of DEXA data could be a limitation, but it has been reported that CT scan density showed a highly signifi cant positive correlation with pathological measurements of vertebral bone density ( 30 ) . As described in the introduction section BMD of the vertebra assessed by chest CT scan is clinically useful to predict vertebral compression fractures that could deteriorate pulmonary functions. Moreover, chest CT scan can detect emphysematous change (LAA) and BMD simultaneously without additional X-ray exposure by DEXA. Th ird the data of the present study subjects lack some confounding factors that could aff ect BMD, for example activity, diet intake (calcium and vitamin D intake), and loss of fat-free mass, since it has been suggested that inactivity could cause osteoporosis in COPD patients ( 31 ) . Th e present study did not include some markers of bone metabolism (for example values for 25-hydroxyvitamin D) and systemic infl ammation either. Future research is needed to assess the eff ect of other factors that were lacking in the present study and to clarify the mechanism of osteoporosis progression with COPD exacerbations.
Conclusions
In conclusion, the present study demonstrated that the decrease in thoracic vertebral BMD was greater in patients with a history of exacerbations than in those without a history of exacerbations. Th ese data suggest that osteoporosis progression should be evaluated in COPD patients, especially in those with a history of frequent exacerbations.
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